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Objective: To examine the efficacy, safety, and tolerability of travoprost 0.004% benzalkonium 
chloride (BAK)-free compared with previous use of latanoprost 0.005% in Japanese patients 
living in the US who had primary open-angle glaucoma or ocular hypertension.
Methods: This was an open-label, multicenter, bilateral, intraindividual, and active-controlled 
study in which 20 Japanese American patients with primary open-angle glaucoma or ocular 
hypertension who had been on latanoprost 0.005% monotherapy were changed to monotherapy 
with travoprost 0.004% BAK-free daily for 12 weeks. Patients were administered the same series 
of tests to evaluate the efficacy, safety, and tolerability of latanoprost at the baseline visit and 
of travoprost BAK-free at the week 12 visit.
Results: No significant difference in mean intraocular pressure (IOP) was observed between 
latanoprost monotherapy at baseline and travoprost BAK-free monotherapy after 12 weeks 
(P = 0.76), nor were significant differences noted in mean ocular hyperemia, visual acuity, cor-
neal fluorescein staining, or overall scores from the Ocular Surface Disease Index. Patients had 
a significantly shorter mean tear breakup time while on latanoprost compared with travoprost 
BAK-free (P = 0.0094). Significantly more patients preferred travoprost BAK-free monotherapy 
over latanoprost monotherapy (14 versus 6; P = 0.011).
Conclusion: The results of this study suggest that Japanese American patients transitioned 
from latanoprost 0.005% monotherapy to travoprost 0.004% BAK-free can expect similar IOP 
control and some improvement in anterior segment signs. This transition study showed a strong 
patient preference for travoprost BAK-free over latanoprost, at a ratio of more than 2:1.
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Introduction
Prostaglandin analogs are among the most common first-line therapies for the treatment 
of elevated intraocular pressure (IOP) associated with glaucoma. Because glaucoma is 
a chronic disease, the long-term safety of prostaglandin analogs is of paramount impor-
tance. However, many prostaglandin analogs contain preservatives that may be toxic to 
the eye.1 The most common preservative in IOP-lowering medications is benzalkonium 
chloride (BAK), a quaternary ammonium compound that causes bacterial cell death 
by lysing cytoplasmic membranes.2 BAK has demonstrated toxicity against both cor-
neal and conjunctival cells when administered in the range of concentrations present 
in ophthalmic medications (0.004–0.02%).2–5 Moreover, in vitro, animal, and clinical 
studies have demonstrated that BAK-containing medications are associated with greater 
toxicity, increased ocular surface damage, and decreased tolerability compared with 
BAK-free preparations.6–10 Latanoprost 0.005% (Xalatan®; Pfizer Inc., New York, NY) Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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contains 0.02% BAK, one of the highest BAK concentrations 
found in ophthalmic preparations. Instead of using BAK as 
a preservative, travoprost 0.004% BAK-free (Travatan Z®; 
Alcon Laboratories, Inc., Fort Worth, TX) contains the alter-
native preservative system SofZia™, containing borate, zinc, 
and sorbitol.9 Although limited research has been published 
on SofZia™, a relatively new preservative, available studies 
report no significant difference in ocular toxicity between 
travoprost BAK-free and preservative-free artificial tears.8,9
Both in vitro and in vivo studies directly comparing 
travoprost BAK-free with latanoprost show that travoprost 
BAK-free is less toxic to the cornea and conjunctiva.6–8,11 
In addition, a transition study by Horsley and Kahook10 also 
reported that patients with reduced tear breakup time who 
transitioned to travoprost BAK-free monotherapy after at 
least one year of latanoprost monotherapy had decreased 
corneal staining, longer tear breakup time, and fewer ocular 
surface disease symptoms, while maintaining equivalent IOP-
lowering efficacy. We were interested to determine whether 
these favorable outcomes noted with travoprost BAK-free 
would be duplicated in Japanese patients, a population that is 
generally underrepresented in clinical studies but is prevalent 
on the island of Hawaii. Therefore, the goal of the current 
study was to examine the efficacy, safety, and tolerability of 
travoprost 0.004% BAK-free compared with previous use of 
latanoprost 0.005% in Japanese patients with primary open-
angle glaucoma or ocular hypertension living in the US.
Methods
This was a prospective, open-label, multicenter, intrain-
dividual, and active-controlled study. The objective of the 
study was to examine the safety, efficacy, and tolerability of 
travoprost BAK-free in Japanese patients on prior latanoprost 
monotherapy. The protocol was approved by all relevant 
institutional review boards and the study was performed in 
compliance with the ethical principles of the Declaration 
of Helsinki and Good Clinical Practice. All participating 
patients provided written informed consent.
Patients
Eligible patients were at least 21 years old with a clinical diag-
nosis of primary open-angle glaucoma or ocular hypertension 
in at least one eye (and a documented history of untreated 
IOP . 21 mmHg) and were of Japanese origin. Japanese 
origin was defined as descended from both maternal and 
paternal Japanese grandparents and Japanese parents (one 
parent could be half-Japanese), and part of the third generation 
or younger to live in the US. They also needed to have been 
treated with latanoprost monotherapy for at least one week 
prior to enrollment and had to have an IOP $16 mmHg in 
at least one eye and #30 mmHg in both eyes at the baseline 
visit. They were required to have a best corrected Snellen 
visual acuity (BCVA) of at least 20/200 in both eyes, and the 
investigator had to consider the patient a good candidate for 
travoprost BAK-free due to a need for improved tolerability 
or reduced IOP over that observed with latanoprost therapy.
Patients were excluded if they met any of the following 
criteria: presence or untreated history of narrow angles with 
or without complete or partial closure in either eye; any 
abnormality preventing reliable applanation tonometry in a 
study eye; any known opacity or patient uncooperativeness that 
restricted adequate examination of the ocular fundus or anterior 
chamber of either eye; concurrent infectious/noninfectious 
conjunctivitis, keratitis, scleritis, blepharitis, or uveitis in either 
eye; conventional intraocular surgery within three months 
prior to screening or laser surgery within two months prior 
to screening in either eye; history of ocular trauma within 
six months prior to screening; risk of visual field or visual 
acuity worsening as a consequence of trial participation, in 
the investigator’s opinion; progressive retinal or optic nerve 
disease from any cause other than glaucoma; women who were 
pregnant, lactating, or of childbearing potential and not using 
a reliable means of birth control; any clinically significant, 
serious, or severe medical or psychiatric condition or severe 
dementia; any condition which, in the opinion of the principal 
investigator, would interfere with optimal participation in the 
study or present a special risk to the patient; participation in 
any other investigational study within 30 days prior to visit 1; 
known history of allergy, sensitivity or poor tolerance to any 
components of the study medications; use of systemic medi-
cations known to affect IOP, which have not been on a stable 
course for seven days prior to visit 2 or an anticipated change 
in the dosage during the course of the study; unwillingness 
to risk the possibility of darkened irides, eyelash changes, or 
periocular pigmentation; history or risk of uveitis or cystoid 
macular edema; history of ocular herpes simplex; anticipated 
use of ocular, dermal, or oral corticosteroids for more than 
two weeks in total during the trial or current chronic use of 
ocular, dermal, or oral corticosteroids; and use of contact lenses 
in the study eye(s). Both eyes of eligible patients could be 
enrolled if both met the inclusion and exclusion criteria.
study design
Patients who were eligible for trial participation after screening 
were continued on latanoprost monotherapy for one additional 
week until the baseline visit. At the baseline visit, patients were 
asked to complete the validated Ocular Surface Disease 
Index (OSDI) questionnaire.12 The OSDI was developed by Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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the Outcomes Research Group at Allergan, Inc. (Irvine, CA) 
to provide a rapid assessment of the severity of symptoms 
of ocular surface disease and their impact on vision-related 
function.13 OSDI scores were classified as normal (0–12), 
mild ocular surface disease symptoms (13–22), moderate 
ocular surface disease symptoms (23–32), and severe ocular 
surface disease symptoms (33–100), as previously described.14 
Evaluations conducted at the baseline visit included BCVA, 
ocular hyperemia grading, slit-lamp biomicroscopy, tear 
breakup time, corneal fluorescein staining, and Goldmann 
applanation tonometry at 4 pm. The patients were then changed 
from BAK-preserved latanoprost monotherapy to travoprost 
ophthalmic solution 0.004% BAK-free administered once 
daily at 8 pm for 12 weeks. Patients returned to the clinic at 
week 4 for a safety assessment (BCVA, slit-lamp biomicros-
copy, and IOP at 4 pm) and at week 12 to undergo final study 
visit evaluations (same as for baseline visit) and to answer a 
study medication preference question. Adverse events were 
collected, monitored, and evaluated throughout the study.
statistics
The primary efficacy variable was the change in IOP from 
latanoprost monotherapy at the baseline visit to travoprost 
BAK-free monotherapy at the week 12 visit and was analyzed 
by a two-tailed paired t-test. A two-tailed paired t-test was also 
utilized to evaluate differences in hyperemia, tear breakup 
time, corneal fluorescein staining, ocular surface disease 
patient questionnaire, and visual acuity. Adverse events and 
patient preference were analyzed by a McNemar test. An 
intent-to-treat average eye analysis was used. An α-level of 
0.05 was used to declare statistical significance. The data were 
analyzed by the PRN Pharmaceutical Research Network, 
LLC (Dallas, TX).
Results
Twenty Japanese American patients were enrolled and 
evaluable for analysis. As shown in Table 1, patients 
had a mean age of 73.1 ± 9.8 years and nearly all (95%) 
had a diagnosis of primary open-angle glaucoma. Nineteen 
patients received latanoprost for one month or less before 
transitioning to travoprost BAK-free and the one remaining 
patient received latanoprost for approximately six weeks. 
No significant difference in mean IOP was observed between 
latanoprost monotherapy at baseline and travoprost BAK-
free monotherapy after 12 weeks (17.0 ± 1.5 mmHg versus 
17.1 ± 1.6 mmHg, P = 0.76, Table 2) nor were significant 
differences noted in mean ocular hyperemia (0.7 ± 0.8 versus 
0.3 ± 0.4, P = 0.064). Patients had a significantly shorter mean 
tear breakup time while on latanoprost monotherapy compared 
with travoprost BAK-free monotherapy (7.6 ± 3.2 sec versus 
9.5 ± 2.3 sec, P = 0.0094). An examination of safety param-
eters revealed no significant changes in visual acuity, corneal 
staining, or slit-lamp biomicroscopy.
Mean OSDI scores were normal at baseline when patients 
were receiving latanoprost monotherapy and remained in the 
normal range (0–12) after 12 weeks on travoprost BAK-free. 
Three adverse events were reported during the study, including 
one case each of inferior superficial punctate epithelial erosion, 
corneal stippling, and increased ocular redness and dryness. 
The patient experiencing increased ocular redness and dryness 
discontinued the study. This adverse event was the only one 
classified as related to treatment. Significantly more patients 
preferred travoprost BAK-free monotherapy compared with 
latanoprost monotherapy (14 versus 6, P = 0.011).
Discussion
Patients with glaucoma are particularly susceptible to 
BAK-induced ocular toxicity because they take BAK-
containing medications chronically, often for decades. In 
both conjunctival and corneal cells, BAK has been found to 
induce apoptosis5,7 and increase proinflammatory cytokine 
Table 1 Patient demographics*
Mean age (years ± standard deviation) 73.1 ± 9.8 
gender (n, %)
Male 9 (45%)
Female 11 (55%)
Ophthalmic history (n, %) 
Primary open-angle glaucoma 19 (95%)
Ocular hypertension 1 (5%)
Cataract 1 (5%)
epiretinal membrane 1 (5%)
Note:  *Two  patients  with  primary  open-angle  glaucoma  also  had  cataract  or 
epiretinal membrane.
Table 2 Mean efficacy and safety measures of latanoprost monotherapy versus travoprost BAK-free monotherapy
Measure* Latanoprost Travoprost BAK-free P value
intraocular pressure (mmhg) 17.0 ± 1.5 17.1 ± 1.6 0.76
Tear film breakup time (sec) 7.6 ± 3.2 9.5 ± 2.3 0.0094
Ocular hyperemia (scale of 0–3) 0.7 ± 0.8 0.3 ± 0.4 0.064
Visual acuity (snellen) 27.9 ± 8.5 28.4 ± 8.0 0.45
Note: *All scores are presented as mean ± standard deviation.
Abbreviation: BAK, benzalkonium chloride.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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elaboration.15 BAK can also produce corneal microvilli loss,8 
conjunctival lymphocyte infiltration,8 and conjunctival goblet 
cell loss.9 Clinical studies have supported the hypothesis that 
BAK-containing ophthalmic medications are detrimental to 
ocular surface health.8–10,16
In the current study, patients had a mean increase of 
almost two seconds in tear breakup time after 12 weeks of 
travoprost BAK-free monotherapy (P = 0.0094). A potential 
explanation for this significant improvement may be provided 
by the fact that BAK-containing latanoprost has been reported 
to produce a loss in conjunctival goblet cells, which has not 
been observed with travoprost BAK-free.9 Because goblet 
cells facilitate ocular surface wettability and tear film stability 
through the secretion of mucin,17 a loss of these cells would be 
expected to destabilize the tear film, leading to decreased tear 
breakup time. The Horsley study, which compared latanoprost 
with travoprost BAK-free and had a study design similar 
to the current study, also reported a significant increase in 
tear breakup time after transition to travoprost BAK-free 
(P , 0.001),10 supporting the results of our study.
Patients in the current study were found to have no 
significant changes in IOP 12 weeks after transitioning from 
latanoprost monotherapy to travoprost BAK-free mono-
therapy, suggesting that the removal of BAK does not affect 
IOP control. With respect to safety, patients had no significant 
changes in visual acuity, corneal staining, or slit-lamp biomi-
croscopy. An examination of ocular hyperemia demonstrated 
a trend toward less hyperemia with travoprost BAK-free, but 
missed statistical significance (P = 0.064) due to the small 
number of patients. This is noteworthy, because studies of 
latanoprost and BAK-containing travoprost have demonstrated 
a modest increase in the incidence and severity of hyperemia 
with travoprost relative to latanoprost.18–20 Results from this 
study suggest that travoprost BAK-free may not have an 
ocular hyperemia disadvantage, although the relatively small 
sample size of this study (n = 40 eyes) may make a modest 
difference difficult to detect. However, the Horsley study 
comparing latanoprost and travoprost BAK-free did dem-
onstrate a significant improvement in corneal staining after 
transition to travoprost BAK-free (P , 0.001).10 While no 
definitive conclusions can be drawn regarding the discrepancy 
between our results and those of Horsley and Kahook, the 
fact that patients in the Horsley study had been on latano-
prost therapy for at least a year may have contributed to the 
different results. In the current study, most patients received 
latanoprost for less than a month, and because corneal damage 
from BAK is cumulative, corneal staining would most likely 
not be affected after only a few weeks of BAK exposure. 
Additionally, our study design did not select for patients with 
ocular surface disease. The patients entered the study with 
normal OSDI scores and ocular staining and, as expected, 
no changes were observed after 12 weeks of dosing with the 
travoprost BAK-free formulation.
The brief duration of latanoprost therapy (#six weeks) prior 
to transitioning to travoprost BAK-free is a limitation of this 
study because it may not have allowed enough time to observe 
differences in IOP and/or adverse effects between treatments. 
A similar study with a longer requirement for latanoprost use 
prior to transition might produce differences in other parameters 
that were not evident in the current study. However, the fact that 
the Japanese patients in this study had a strong preference for 
travoprost BAK-free after such a short time taking latanoprost 
suggests strongly that patients perceived travoprost BAK-free 
to be more tolerable than latanoprost.
In conclusion, this study, albeit in a limited number of 
patients, demonstrates that patients of Japanese origin with 
primary open-angle glaucoma or ocular hypertension can be 
changed from latanoprost 0.005% monotherapy to travoprost 
0.004% BAK-free monotherapy, with similar IOP control and 
similar or improved safety and tolerability. Based on these 
results, it is appropriate to expect that patients would view 
such a transition favorably.
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